Compare Citius Pharmaceuticals Inc (CTXR) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs FedEx Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while FedEx Corporation trades at $291.71 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 5069× Citius Pharmaceuticals Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and FedEx Corporation for 87 Days on average.
| CTXR | FDX | |
|---|---|---|
Market Cap | $13.62M | $69.04B |
Volume | 132,438 | 1,287,367 |
Sector | Health | Industrials |
52-Week High | $1.82 | $339.35 |
52-Week Low | $0.48 | $180.87 |
Typical Hold Time | 17 Days | 87 Days |
Enterprise Value | $3.79M | $98.68B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
FedEx (FDX) trades at $291.73, up 0.93% with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 15.73 and net income margin of 4.68%, though revenue has declined from $93.5B in 2022 to $87.9B in 2025. Recent developments include a $300 million electric truck order and strong shareholder support for management.
Wall Street remains bullish with a $307.55 consensus target (57% buy ratings), but rising fuel costs and competitive pressures pose risks. The stock offers value pricing with P/S of 0.74 and positive cash flow projection for 2026, though technical indicators suggest near-term resistance around $294-299.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
